On October 8, Twist Bioscience Corp fell 5.63% in regular trading, trading at $146.975 per share, with Turnover of $47.7125 million.

The decline followed Jefferies initiating coverage on the stock with a Hold rating and a $150 price target, which offered minimal upside from current levels and failed to provide a positive catalyst.

Analyst consensus data indicated an average overweight rating and a mean price target of approximately $150.33, suggesting limited near-term appreciation potential and reinforcing a cautious market stance on the synthetic DNA company's valuation.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products, serving customers in therapeutics, diagnostics, agriculture, and data storage through its proprietary silicon-based DNA writing platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)